Safety of cluster specific immunotherapy with a modified high-dose house dust mite extract.
Eur Ann Allergy Clin Immunol
; 45(3): 78-83, 2013 May.
Article
en En
| MEDLINE
| ID: mdl-23862396
ABSTRACT
INTRODUCTION:
Although the efficacy and safety of high dose hypoallergenic mite subcutaneous immunotherapy (SCIT) using a conventional administration schedule has already been demonstrated, there is no reported experience on the safety of these extracts with cluster schedules. We wanted to determine whether the use of a cluster schedule of a hypoallergenic allergen with a high concentration of house dust mite allergens commonly used in normal practice was safe and well-tolerated in patients with dust mite allergy. MATERIAL ANDMETHODS:
Multicentre, observational, retrospective study of dust mite allergic patients treated with a cluster schedule of SCIT (Acaroid; Day 1 300/300 therapeutic units, TU--Day 8 1000/1000 TU--Day 15 3000/3000 TU) in 23 Spanish sites.RESULTS:
Cluster schedule was used on 434 patients (40.1% children), with a total of 3256 doses (38.2% in children). There were 88 clinically relevant adverse reactions, 79 out of them local and 9 systemic (but mild-moderate) that amounted to 2.7% of all the administered doses. All the patients fulfilled the cluster schedule.CONCLUSIONS:
Cluster schedule with high dose hypoallergenic mite-SCIT was safe and well-tolerated in routine clinical practice. Therefore, its use could reduce the costs and time needed to achieve the desired maintenance dose and increase compliance.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Desensibilización Inmunológica
/
Pyroglyphidae
/
Antígenos Dermatofagoides
/
Hipersensibilidad
Tipo de estudio:
Observational_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Animals
/
Child
/
Child, preschool
/
Humans
/
Middle aged
Idioma:
En
Revista:
Eur Ann Allergy Clin Immunol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2013
Tipo del documento:
Article
País de afiliación:
España